Latest news with #RP1
Business Wire
2 days ago
- Business
- Business Wire
RP1 Launches the World's First Metaverse Browser
LONG BEACH, Calif.--(BUSINESS WIRE)--The world is on the brink of the most significant software transition since the advent of the web browser. Today, we browse flat websites on handheld screens. Tomorrow, we'll browse 3D spatial content blended with the real world through AR and VR devices. The browser becomes a gateway to the first open ecosystem for 3D content. In the future, businesses won't just have websites; they'll have interactive, 3D locations where AI greets customers, guides them to products, and powers everything from employee training to inventory. This transformation will revolutionize every industry. Share Today, RP1, a leader in spatial computing software and infrastructure, unveils the world's first Metaverse Browser and ground-breaking technologies to deliver on that vision. The future of the spatial internet will consist of persistent 3D content and millions of real-time, third-party services. This monumental technology shift will dramatically transform how people interact and businesses operate. In the future, businesses won't just have websites; they'll have interactive, 3D locations where AI greets customers, guides them to products, and powers everything from employee training to inventory. This transformation will revolutionize every industry from retail and hotels to hospitals, airports, and schools. 'No single company will own the infrastructure of the metaverse — it must be open,' said Sean Mann, Co-Founder and CEO of RP1. 'RP1 lets developers and businesses build and deploy spatial software on their own server infrastructure, with full ownership and control while remaining instantly discoverable and accessible across devices — no pre-compiled app downloads or installations are required, just like web browsing. Anyone can experience it now at Major players — Apple, Meta, Google, Samsung — are racing to develop AR glasses that will eventually replace smartphones. But while these companies are having trouble solving for today's needs, RP1 is solving for what comes next: a truly open, spatial internet made of millions of real-time, interconnected services. Any individual or company will be able to experience and build spaces or services freely with third-party tools, as opposed to other walled garden 3D platforms. 'Current browsers like Chrome and Safari were not designed for immersive, real-time 3D content and services for AR glasses,' added Mann. 'RP1's 3D Browser is built for a world of real-time, volumetric, spatial experiences. It connects the entire global population with 3D content inside a single, persistent XR ecosystem — across virtual and physical locations spanning education, commerce, entertainment, digital twins, smart cities, work, transportation, and even space exploration.' This marks the first real software foundation for the spatial internet, featuring industry-first technologies. Breakthrough Innovations Behind RP1's Metaverse Browser: Unprecedented Scalability to connect the entire world's population (vs. 40 users per instance/server in current 3D platforms like Roblox or Meta Horizon Worlds) in a single unsharded architecture with full spatial audio and 6DOF, making it seamless to connect with anyone, at any time, and with any content. Unlimited Map that includes a fully-continuous, 1:1 scale digital twin of Earth, our solar system, and the farthest reaches of the universe, for frictionless discovery and navigation of augmented and virtual spatial content. Real-time API that enables any real-time third-party service, including AI, payments, games, and businesses (stores, hotels, etc.) to easily connect to the 3D browser across both augmented and virtual environments. Decentralized Hosting for businesses to run their own worlds and services on their own servers, not inside a closed platform like Roblox or Meta. 'I'm excited about the first metaverse browser solution that creates an open and scalable XR ecosystem. Like Chrome for websites, it has the potential to remove friction/limitations for studios, brands and agencies looking to activate inside the XR and UGC gaming space. It's early days but the RP1 point of view is fresh, bold and unique.' added Nic Hill, Co-Founder & Chief Innovation Officer at Sawhorse. With RP1, the spatial internet isn't a concept — it's here. And it's open for everyone on all devices. Check out the RP1 Demo at AWE, Booth #528. For detailed information about these revolutionary technologies, visit About RP1 RP1 is a pioneer in the technology industry, shaping the future of the spatial internet. RP1's mission is to connect the world's population with innovative technologies that bring us closer, and enhance our daily lives with immersive experiences. Its proprietary real-time networking and Statabase technologies allow users to experience immersive 3D environments streamed instantly to any device. With open protocols and web-like infrastructure, RP1 empowers creators, developers, and businesses to build spatial applications that work like the web - frictionless, open, and scalable to billions. RP1 was named 'Innovation of the Year' at the WebXR Awards 2023 by the Poly Awards, and a multi-award finalist at the VR Awards 2024.
Business Insider
02-06-2025
- Health
- Business Insider
Replimune presents two posters on data updates for RP1 at 2025 ASCO
Replimune (REPL) Group presented two posters highlighting data updates for RP1 at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting taking place May 30-June 3 in Chicago. The poster included an analysis from the IGNYTE clinical trial of RP1 plus nivolumab in the cohort of anti-PD-1 failed melanoma patients. In the trial, the objective response rate was 32.9% using RECIST 1.1. The complete response rate was 15.0% and landmark overall survival rates at 1, 2, and 3 years were 75.3%, 63.3%, and 54.8% respectively. Median OS has not been reached. Patients experienced numerically higher objective response rates after receiving deep injections compared with superficial injections only. Deep responses were observed in injected and non-injected lesions. The ORR by injection type using RECIST 1.1 was 29.8% when only superficial lesions were injected, 42.9% for deep/visceral plus superficial injections injected, and 40.9% when only deep/visceral lesions were injected. There was a greater than or equal to30% reduction in 93.6% of injected lesions and 79.0% of non-injected lesions. Liver and lung injections had a tolerable safety profile. No bleeding events were reported after liver injection. Lung injections were associated with low rates of pneumothorax events, which were typically of low grade and manageable. Overall, these data support the safety and efficacy of deep/visceral injections and demonstrate the development of a robust systemic anti-tumor response following treatment with RP1 plus nivolumab.
Yahoo
01-06-2025
- Business
- Yahoo
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. 'The new analyses we presented from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma confirms our belief in the systemic activity of the combination, and also shows robust responses in injected liver and lung lesions with an acceptable safety profile,' said Kostas Xynos, M.D., Chief Medical Officer of Replimune. 'Additional data also presented at the meeting shows that RP1 can be handled safely with no additional biosafety protocols required confirming that standard disinfection procedures are sufficient for clean up.' Key findings are outlined below. Poster Presentation: Response analysis for injected and non-injected lesions and the safety and efficacy of superficial and deep RP1 injection in the registrational cohort of anti-PD-1-failed melanoma patients of the IGNYTE trial (Track: Melanoma/Skin Cancers; June 1, 2025, 9:00 am – 12:00 pm CDT; Location: Hall A, Board 20; Abstract: 9537) The poster included an analysis from the IGNYTE clinical trial of RP1 plus nivolumab in the cohort of anti-PD-1 failed melanoma patients (n=140). In the trial, the objective response rate (ORR) was 32.9% using RECIST 1.1. The complete response rate was 15.0% and landmark overall survival (OS) rates at 1, 2, and 3 years were 75.3%, 63.3%, and 54.8% respectively. Median OS has not been reached. Patients experienced numerically higher objective response rates after receiving deep injections (± superficial) compared with superficial injections only. Deep responses were observed in injected and non-injected lesions. The ORR by injection type using RECIST 1.1 was 29.8% when only superficial lesions were injected, 42.9% for deep/visceral plus superficial injections injected, and 40.9% when only deep/visceral lesions were injected. There was a ≥30% reduction in 93.6% (73/78) of injected lesions and 79.0% (94/119) of non-injected lesions. The kinetics of response were similar in injected vs non-injected lesions. Of the non-injected visceral organ lesions in responding patients, 96.2% (50/52) showed reduction from baseline, with 65.4% reduced by ≥30%. RP1 injections directly into the lung and liver were generally well tolerated and resulted in few organ-specific adverse events that were easily managed. Liver and lung injections had a tolerable safety profile. No bleeding events were reported after liver injection. Lung injections were associated with low rates of pneumothorax events, which were typically of low grade and manageable. Overall, these data support the safety and efficacy of deep/visceral injections and demonstrate the development of a robust systemic anti-tumor response following treatment with RP1 plus nivolumab. Poster Presentation: Biosafety analysis from the skin cancer cohorts in the IGNYTE clinical trial of RP1 (Track: Melanoma/Skin Cancers; June 1, 2025, 9:00 am – 12:00 pm CDT; Location: Hall A, Board 17; Abstract: 9534) RP1 was assessed in various samples taken from patients. This demonstrated that RP1 DNA is primarily detected at the injection site, consistent with RP1 replication in the tumor, and much more rarely on dressings, in blood, on mucous membranes or in urine. In all cases, live RP1 was only rarely if ever detected, demonstrating that while residual RP1 DNA may be present, this does not indicate the presence of live RP1 There were no systemic herpetic infections in patients or reports of HSV-1 infections in contacts. RP1 is completely neutralized using standard disinfectants within 30 seconds of contact, confirming that standard disinfection procedures are sufficient for RP1 clean-up. Collectively these data demonstrate that the likelihood of transmission of RP1 to patients' contacts or into the external environment is minimal, with no transmission having been reported to date. Both posters will be available on the Company website under Events and Presentations. About RP1RP1 is Replimune's lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. About RP2RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP-R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity. About ReplimuneReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit Forward Looking StatementsThis press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, the regulatory review process and timing of potential product approval, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as 'could,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'should,' 'will,' 'would,' or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Investor InquiriesChris BrinzeyICR Media InquiriesArleen GoldenbergReplimune917.548.1582 media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034)
As per DelveInsight's estimates, among the 7MM, the US captured the highest market of intra-tumoral cancer therapies of nearly USD 74 million in 2024, which is expected to increase due to the launch of emerging therapies such as CAN-2409, RP1 (vusolimogene oderparepvec), SP-002 (ASN-002), Bizaxofusp (MDNA55), and others. LAS VEGAS, May 19, 2025 /PRNewswire/ -- DelveInsight's Intra-tumoral Cancer Therapies Market report includes a comprehensive understanding of current treatment practices, emerging intra-tumoral cancer therapies, market share of individual therapies, and current and forecasted intra-tumoral cancer therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Intra-tumoral Cancer Therapies Market Report Currently, only three Intra-tumoral Cancer Therapies are approved; namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), approved in the US and Europe in 2015, DELYTACT (teserpaturev/G47Δ; Daiichi Sankyo) approved in Japan in 2021, and HENSIFY in Europe in 2019. As per DelveInsight's analysis, the total market size of intra-tumoral cancer therapies in the 7MM was USD 109 million in 2024 and is projected to grow during the forecast period (2025-2034). In 2024, the total cases of selected indication (based on current landscape and pipeline activity) were 8.9 million in the 7MM, which is anticipated to increase by 2034. Leading intra-tumoral cancer therapies companies, such as Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir, Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others, and others, are developing novel intra-tumoral cancer therapies that are expected to enter the intra-tumoral cancer therapies market in the coming years. Some of the key intra-tumoral cancer therapies in the pipeline include INT230-6, Vusolimogene oderparepvec (RP1), Nidlegy (Daromun), G207, Ilixadencel (INTUVAX), Tigilanol tiglate, SP-002 (ASN-002), BO-112, Bizaxofusp (MDNA55), and others. In March 2025, NANOBIOTIX announced topline data from the completed dose-escalation portion of a Phase I study, conducted under the sponsorship of The University of Texas MD Anderson Cancer Center, evaluating JNJ-1900 (NBTXR3) activated by radiation therapy as a second-line or later (2L+) treatment for patients with locally advanced NSCLC eligible for re-irradiation. In March 2025, NANOBIOTIX announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV. The amendment removes NANOBIOTIX's funding obligation for NANORAY- 312 and releases Johnson & Johnson from select future potential milestone payments while safeguarding NANOBIOTIX's path to sustainable cash flow through significant potential milestone payments. In March 2025, Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel's lead asset, CAN-2409. In January 2025, Lokon Pharma AB announced that the Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) for the company's product candidate LOAd703 for the treatment of pancreatic cancer. In January 2025, Intensity Therapeutics announced that the Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INT230-6, INVINCIBLE-3) without modification based on data reviewed from July 2024 to December 2024. Some factors, such as the precedence of failure of emerging therapies, insufficient knowledge about Intra-tumoral Cancer Therapies, and several other drawbacks, might hinder the Intra-tumoral Cancer Therapies market growth. Discover which therapies are expected to grab the intra-tumoral cancer therapies market share @ Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Market Dynamics The intra-tumoral cancer therapies market dynamics are expected to change in the coming years. Various classes of intra-tumoral immunotherapies, including radioenhancer nanoparticles, recombinant fusion proteins, oncolytic therapy, gene therapy, synthetic dsRNA complexes, and others, are currently in preclinical and clinical development. These therapies increase drug concentration and availability within the tumor microenvironment while limiting systemic exposure and reducing the likelihood of immune-related side effects in other parts of the body. Intra-tumoral therapeutic strategies offer a powerful approach to in situ vaccine development, utilizing immune-stimulating agents to trigger local and systemic anti-tumor immune responses. Additionally, the ability of intra-tumoral immunotherapy combinations to elicit both T-cell and B-cell antitumor responses presents a potential strategy to overcome immune escape mechanisms, such as the loss of HLA-I expression on tumor cells, which are often associated with immune checkpoint therapy monoclonal antibody monotherapies. Furthermore, potential therapies are being investigated, and it is safe to predict that the treatment space will significantly impact the intra-tumoral cancer therapies market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the intra-tumoral cancer therapies market in the 7MM. However, several factors may impede the growth of the intra-tumoral cancer therapies market. The lack of standardized guidelines for intra-tumoral immunotherapy delivery results in variations in lesion selection, injection frequency, and needle technique, which directly affect treatment outcomes and safety. Patients are required to visit clinics for each dosing session, and the administration necessitates both trained radiologists and logistics support alongside skilled physicians. While research into intra-tumoral therapies has grown in recent years, several therapies, such as tilsotolimod/Ipilimumab, sotigalimab (APX005M), and vidutolimod (CMP-001), have failed clinical trials, impacting the market. Additionally, tumors with high intra-tumoral heterogeneity may lead to poorer clinical outcomes for patients. Intra-tumoral Cancer Therapies Therapeutics Market Although significant progress has been made in cancer treatment through methods like surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, many of these treatments still face limitations such as systemic toxicity, inadequate tumor penetration, and poor targeting. These issues contribute to high mortality rates, underscoring the need for more precise and localized treatment options. Recently, cancer treatment strategies have increasingly focused on alternative delivery methods, including intra-tumoral administration. This approach is being actively researched, with several therapeutic candidates—such as immune receptor agonists, viral therapies, fusion proteins, monoclonal antibodies, and gene therapies—currently undergoing preclinical and clinical trials. Intra-tumoral immunotherapy, which involves directly delivering agents into or near the tumor site, is emerging as a promising approach. This strategy aims to boost localized immune responses while reducing systemic side effects. The first oncolytic virus, IMLYGIC (T-Vec; Amgen), was approved by the US FDA for treating unresectable melanoma lesions after surgery, following a Phase III trial. The European Commission approved the treatment of advanced melanoma in 2015. In 2019, Nanobiotix's HENSIFY (NBTXR3), a hafnium oxide nanoparticle therapy combined with radiation, received European approval for soft tissue sarcoma, with plans for data releases through 2025-2026 across multiple cancers. For STS the drug is approved in Europe but not yet launched. In Japan, DELYTACT (G47∆; Daiichi Sankyo) was granted conditional approval for malignant glioma, marking the first oncolytic virus for brain cancer, and is still under evaluation for its clinical benefits. IMLYGIC from Amgen is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors. Despite the initial hype for this exciting intra-tumoral mode of cancer gene therapy, IMLYGIC's debut did not translate into much commercial success in the melanoma market. Limitations of the intra-tumoral administration, no statistically significant benefit in overall survival (OS), and the intense competition from immune checkpoint inhibitors (ICIs) due to their efficacy and manageable side effects are some of the main factors for ithe nsignificant revenues of this novel therapy. Learn more about the FDA-approved intra-tumoral cancer therapies @ Intra-tumoral Cancer Therapies Treatment Key Emerging Intra-tumoral Cancer Therapies and Companies The emerging pipeline of intra-tumoral cancer therapies is robust, including drugs from key players such as Candel Therapeutics (CAN-2409), Lytix Biopharma/Verrica Pharmaceuticals (LTX-315 [VP-315]), CEI-SCI (MULTIKINE), Philogen (Daromun [NIDLEGY; a combo of L19IL2 + L19TNF]), Replimune (RP2 and RP1 [vusolimogene oderparepvec]), Highlight Therapeutics (BO-112), Cytovation ASA (CY-101), Intensity Therapeutics (INT230-6), Ascendis Pharma (TransCon IL-2 β⁄γ), Treovir/Matica Biotechnology (G207), QBiotics (Tigilanol tiglate), NanOlogy (NanoPac), EpicentRx (AdAPT-001), Medicenna Therapeutics (Bizaxofusp [MDNA55]), and others. RP1 (vusolimogene oderparepvec), Replimune's lead product candidate, is based on a proprietary strain of Herpes Simplex Virus (HSV) engineered with a fusogenic protein (GALV-GP R-) and GM-CSF to enhance tumor killing potency, immunogenicity, and activation of a systemic antitumor immune response. In November 2024, Replimune announced that the FDA granted Breakthrough Therapy Designation (BTD) to RP1 in combination with nivolumab for the treatment of advanced melanoma in adult patients who have previously received an anti-PD1 regimen. Nidlegy is a biopharmaceutical product, proprietary to Philogen, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF, which are manufactured independently and which are mixed prior to intralesional administration. In July 2024, Philogen and Sun Pharmaceutical announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy. CAN-2409 (Candel Therapeutics) is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the tumor. In March 2025, according to the company's corporate highlights, the preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer are underway, with submission expected in Q4 2026. The anticipated launch of these emerging therapies are poised to transform the intra-tumoral cancer therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the intra-tumoral cancer therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about intra-tumoral cancer therapies clinical trials, visit @ Intra-tumoral Cancer Therapies Intra-tumoral Cancer Therapies Overview Cancer is a highly diverse disease, with its signs, symptoms, and treatments varying across different types, making it crucial to create targeted therapies for individual patients. Current treatment options for cancer include immunotherapy, radiotherapy, chemotherapy, targeted drug therapies, and more. While these approaches have improved OS and patient outcomes, they still have limitations and are not effective for everyone. Researchers are therefore working to develop new treatments that can overcome these challenges, with intra-tumoral cancer therapies emerging as a promising strategy. Intra-tumoral immunotherapy represents an innovative approach, where sophisticated antibodies are directly injected into tumors instead of being administered intravenously. This method focuses on delivering immunostimulatory agents straight into primary or metastatic tumor sites to initiate or enhance an antitumor immune response. Normally, the immune system detects and eliminates early tumors, but in immunosuppressive tumor environments, malignant cells can proliferate undetected. Regulatory T cells (Tregs), drawn to the tumor by chemokines, suppress Antigen-Presenting Cells (APCs) that would otherwise trigger an immune attack on tumor antigens. Moreover, tumor cells often release anti-inflammatory and regulatory cytokines like TGF-β and IL-10, which promote tumor growth and inhibit dendritic cell (DC) activation. To counteract this immunosuppressive environment, immunostimulants can be introduced. These agents work by attracting immune cells to the tumor or by activating the immune system to recognize and destroy cancer cells. Immunostimulants activate immune cells in the presence of tumor antigens, allowing them to travel to lymph nodes, where they stimulate tumor antigen-specific T cells through cross-presentation. These activated T cells can then return to the tumor or spread to distant tumors, leading to the targeted destruction of cancer cells. Intra-tumoral Cancer Therapies Epidemiology Segmentation In 2024, the total indication-wise treated cases of Intra-tumoral Cancer Therapies were 3.3 million in the 7MM, which is anticipated to increase by 2034. The intra-tumoral cancer therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Selected Indications Indication-wise Target Patient Pool of Intra-tumoral Cancer Therapies Indication-wise Treated Cases of Intra-tumoral Cancer Therapies Intra-tumoral Cancer Therapies Report Metrics Details Study Period 2020–2034 Intra-tumoral Cancer Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Intra-tumoral Cancer Therapies Market CAGR (in the 7MM) 31.3 % Intra-tumoral Cancer Therapies Market Size in 2024 (in the 7MM) USD 109 Million Key Intra-tumoral Cancer Therapies Companies Amgen, Nanobiotix, Daiichi Sankyo, Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir and Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others Key Intra-tumoral Cancer Therapies IMLYGIC (Talimogene Laherparepvec), DELYTACT (teserpaturev), HENSIFY, SP-002 (ASN-002), RP2, RP1 (vusolimogene oderparepvec), TransCon IL-2 β/γ, BO-112, CY-101, INT230-6, G207, Tigilanol Tiglate, NanoPac, LOAd703, AdAPT-001, Bizaxofusp (MDNA55), Nidlegy (L19IL2/L19TNF), CAN-2409, LTX-315, MULTIKINE and others. Scope of the Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Therapeutic Assessment: Intra-tumoral current marketed and emerging therapies Intra-tumoral Cancer Therapies Market Dynamics: Conjoint Analysis of Emerging Intra-tumoral Cancer Therapies Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Intra-tumoral Cancer Therapies Market Access and Reimbursement Discover more about intra-tumoral cancer therapies in development @ Intra-tumoral Cancer Therapies Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Intra-tumoral Cancer Therapy Market Overview at a Glance 6.1 Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2025 6.2 Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2034 7 Background and Overview 7.1 Introduction 7.2 History of Intra-tumoral Cancer Therapies 7.3 Mechanism of Intra-tumoral Cancer Therapies 7.4 Tumor Properties to Consider for Intra-tumoral Cancer Therapies 7.5 Categories of Intra-tumoral Cancer Therapies 7.6 Advantages of Intra-tumoral Cancer Therapies 7.7 Limitations of Intra-tumoral Cancer Therapies 7.8 Emerging Therapies and Future Directions 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases of Selected Indications in the 7MM 8.3.2 Indication-wise Eligible Cases in the 7MM 8.3.3 Indication-wise Treated Cases in the 7MM 9 Marketed Therapies 9.1 Key Cross of Marketed Therapies 9.2 IMLYGIC (talimogene laherparepvec): Amgen 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development Activities 9.2.4.1 Clinical Trials Information 9.2.5 Safety and Efficacy 9.2.6 Analyst View 9.3 DELYTACT (teserpaturev): Daiichi Sankyo 9.3.1 Product Description 9.3.2 Regulatory Milestones 9.3.3 Other Developmental Activities 9.3.4 Safety and Efficacy 9.3.5 Analyst View 10 Emerging Drugs 10.1 Key Competitors 10.2 HENSIFY (JNJ-1900, NBTXR3): NANOBIOTIX/Johnson & Johnson 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development Activities 10.2.4.1 Clinical Trials Information 10.2.5 Safety and Efficacy 10.2.6 Analyst View 10.3 INT230-6: Intensity Therapeutics 10.3.1 Product Description 10.3.2 Other Development Activities 10.3.3 Clinical Development 10.3.3.1 Clinical Trial Information 10.3.4 Safety and Efficacy 10.3.5 Analyst View 10.4 RP1 (vusolimogene oderparepvec): Replimune 10.4.1 Product Description 10.4.2 Other Developmental Activities 10.4.3 Clinical Development 10.4.3.1 Clinical Trial Information 10.4.4 Safety and Efficacy 10.4.5 Analyst View 10.5 Nidlegy (Daromun): Philogen S.p.A 10.5.1 Product Description 10.5.2 Other Developmental Activities 10.5.3 Clinical Development 10.5.3.1 Clinical Trials Information 10.5.4 Safety and Efficacy 10.5.5 Analyst View 10.6 RP2: Replimune 10.6.1 Product Description 10.6.2 Other Developmental Activities 10.6.3 Clinical Development 10.6.3.1 Clinical Trial Information 10.6.4 Safety and Efficacy 10.6.5 Analyst View 10.7 Cotsiranib (STP705): Sirnaomics 10.7.1 Product Description 10.7.2 Other Development Activity 10.7.3 Clinical Development 10.7.3.1 Clinical Trial Information 10.7.4 Safety and Efficacy 10.7.5 Analyst View 10.8 BO-112: Highlight Therapeutics 10.8.1 Product Description 10.8.2 Other Developmental Activities 10.8.3 Clinical Development 10.8.3.1 Clinical Trial Information 10.8.4 Safety and Efficacy 10.8.5 Analyst View 10.9 SP-002 (ASN-002): Stamford Pharmaceuticals/Ascend Biopharmaceuticals 10.9.1 Product Description 10.9.2 Other Developmental Activities 10.9.3 Clinical Development 10.9.3.1 Clinical Trial Information 10.9.4 Safety and Efficacy 10.9.5 Analyst View 10.10 TransCon IL-2 β/γ: Ascendis Pharma 10.10.1 Product Description 10.10.2 Other Development Activity 10.10.3 Clinical Development 10.10.3.1 Clinical Trial Information 10.10.4 Safety and Efficacy 10.10.5 Analyst View 10.11 Ilixadencel (INTUVAX): Mendus 10.11.1 Product Description 10.11.2 Other Developmental Activities 10.11.3 Clinical Development 10.11.3.1 Clinical Trial Information 10.11.4 Safety and Efficacy 10.11.5 Analyst View 10.12 Tigilanol Tiglate: QBiotics 10.12.1 Product Description 10.12.2 Other Development Activity 10.12.3 Clinical Development 10.12.3.1 Clinical Trial Information 10.12.4 Safety and Efficacy 10.12.5 Analyst View 10.13 NanoPac (LSAM-PTX): NanOlogy 10.13.1 Product Description 10.13.2 Other Developmental Activities 10.13.3 Clinical Development 10.13.3.1 Clinical Trial Information 10.13.4 Safety and Efficacy 10.13.5 Analyst View 10.14 G207: Treovir and Matica Biotechnology 10.14.1 Product Description 10.14.2 Other Development Activities 10.14.3 Clinical Development 10.14.3.1 Clinical Trial Information 10.14.4 Safety and Efficacy 10.14.5 Analyst View 10.15 Lerapolturev: Istari Oncology 10.15.1 Product Description 10.15.2 Other Development Activities 10.15.3 Clinical Development 10.15.3.1 Clinical Trial Information 10.15.4 Safety and Efficacy 10.15.1 Analyst View 10.16 Nelitolimod (SD-101): TriSalus Life Sciences 10.16.1 Product Description 10.16.2 Other Developmental Activities 10.16.3 Clinical Development 10.16.3.1 Clinical Trial Information 10.16.4 Safety and Efficacy 10.16.5 Analyst View 10.17 LOAd703 (Delolimogene mupadenorepvec): Lokon Pharma AB 10.17.1 Product Description 10.17.2 Other Development Activity 10.17.3 Clinical Development 10.17.3.1 Clinical Trial Information 10.17.4 Safety and Efficacy 10.17.5 Analyst View 10.18 AdAPT-001: EpicentRx 10.18.1 Product Description 10.18.2 Other Developmental Activities 10.18.3 Clinical Development 10.18.3.1 Clinical Trial Information 10.18.4 Safety and Efficacy 10.18.5 Analyst View 10.19 Bizaxofusp (MDNA55): Medicenna Therapeutics 10.19.1 Product Description 10.19.2 Other Developmental Activities 10.19.3 Clinical Development 10.19.3.1 Clinical Trial Information 10.19.4 Safety and Efficacy 10.19.5 Analyst View 10.20 CY-101 (CyPep-1): Cytovation ASA 10.20.1 Product Description 10.20.2 Other Developmental Activities 10.20.3 Clinical Development 10.20.3.1 Clinical Trial Information 10.20.4 Safety and Efficacy 10.20.5 Analyst View 10.21 VG161: Virogin Biotech 10.21.1 Product Description 10.21.2 Other Developmental Activities 10.21.3 Clinical Development 10.21.3.1 Clinical Trial Information 10.21.4 Safety and Efficacy 10.21.5 Analyst View 10.22 CAN-2409: Candel Therapeutics 10.22.1 Product Description 10.22.2 Other Developmental Activities 10.22.3 Clinical Development 10.22.3.1 Clinical Trial Information 10.22.4 Safety and Efficacy 10.22.5 Analyst View 10.23 LTX-315: Lytix Biopharma 10.23.1 Product Description 10.23.2 Other Developmental Activities 10.23.3 Clinical Development 10.23.3.1 Clinical Trial Information 10.23.4 Safety and Efficacy 10.23.5 Analyst View 10.24 Multikine: CEI-SCI 10.24.1 Product Description 10.24.2 Other Developmental Activities 10.24.3 Clinical Development 10.24.3.1 Clinical Trial Information 10.24.4 Safety and Efficacy 10.24.5 Analyst View 11 Intra-tumoral Cancer Therapies: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Key Market Forecast Assumptions 11.3.1 Cost Assumptions and Rebates 11.3.2 Pricing Trends 11.3.3 Analogue Assessment 11.3.4 Launch Year and Therapy Uptakes 11.4 Conjoint Analysis 11.5 Total Market Size of Intra-tumoral Cancer Therapies by Indications in the 7MM 11.6 Total Market Size by Therapies in the 7MM 11.7 United States Market Size 11.7.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in the United States 11.7.2 Total Market Size by Therapies in the United States 11.8 EU4 and the UK Market Size 11.8.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in EU4 and the UK 11.8.2 Total Market Size by Therapies in EU4 and the UK 11.9 Japan 11.9.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in Japan 11.9.2 Total Market Size by Therapies in Japan 12 Unmet Needs 13 SWOT Analysis 14 KOL Views 15 Market Access and Reimbursement 15.1 The United States 15.1.1 Centre for Medicare and Medicaid Services (CMS) 15.2 EU4 and the UK 15.2.1 Germany 15.2.2 France 15.2.3 Italy 15.2.4 Spain 15.2.5 The United Kingdom 15.3 Japan 15.3.1 MHLW 15.5 Market Access and Reimbursement of Intra-tumoral Cancer Therapies 15.5.1 United States: Assistance programs 15.5.2 United Kingdom: The National Institute for Health and Care Excellence (NICE) Assessment 15.5.3 Germany: The Federal Joint Committee (G-BA) resolutions 15.5.4 Japan: Chuikyo Assessment 16 Appendix 16.1 Bibliography 16.2 Report Methodology 17 DelveInsight Capabilities 18 Disclaimer 19 About DelveInsight Related Reports Oncolytic Virus Market Oncolytic Virus Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of oncolytic virus, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus companies, including Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, among others. Oncolytic Virus Competitive Landscape Oncolytic Virus Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus companies, including Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel Therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NSCLC companies including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-04-2025
- Health
- Yahoo
New cancer treatment available on NHS described as 'early Christmas present'
A cancer treatment described as 'the best early Christmas present I could've asked for', has been given approval. KIMMTRAK, a treatment for metastatic uveal melanoma, an aggressive form of eye cancer, has been approved by the FDA and NICE. The NHS has fast-tracked the treatment to hundreds of patients across England. Professor Peter Johnson, NHS national clinical director for cancer, said: "This type of melanoma is difficult to treat when it has spread in the body, so it is great news that the NHS can now offer this pioneering treatment, giving people an option that can extend their lives and offer them valuable extra time with their families and friends." Bahija Jallal, chief executive officer of Immunocore, said: "Every year, hundreds of people are diagnosed with metastatic uveal melanoma who, until now, had no approved treatment options. "KIMMTRAK is the first therapy to demonstrate a survival benefit to patients with this disease and we are focused on making KIMMTRAK available as quickly as possible." Elsewhere, Adaptimmune has received a Breakthrough Therapy Designation for lete-cel, a T-cell therapy used to treat synovial sarcoma, a rare form of cancer. Replimune has also secured FDA priority review and a Biologics License Application acceptance for RP1, a treatment for advanced melanoma. Sushil Patel, chief executive officer at Replimune, said: "There are limited treatment options and a significant unmet need for patients with advanced melanoma."
